Oncology

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

Despite the toll chemotherapy can take on the body, experts say it's possible for athletes to exercise while undergoing treatment for cancer.

Among 598 trials published between 2003 and 2018, only 107 had a female corresponding author, though women made up anywhere from 27% to 39% of academic oncologists during this time period. 

Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.

The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

A study in JAMA Oncology evaluated re-administration of immune checkpoint blockade in cancer patients who experienced a grade 2 or higher immune-related adverse event.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

A review and meta-analysis in JAMA Oncology evaluated the incidence of treatment-related adverse events in patients receiving PD-1 or PD-L1 therapy.

The phase II KEYNOTE-158 basket trial evaluated single-agent pembrolizumab in patients with previously treated advanced cervical cancer.

Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.

A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.

Experts shared the challenges they've encountered in integrating novel treatments such as CAR T-cell therapy into practice at the 2019 NCCN Annual Conference.

A systematic review in JAMA Oncology examined the safety and efficacy of immune checkpoint inhibitors in advanced-stage cancer patients with HIV infection.

The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.

An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?

Results of the 2-year follow-up analysis of the pivotal KEYNOTE-024 trial were recently published in the Journal of Clinical Oncology.

The results of the study add to the growing body of literature regarding potential biomarkers for response to immune checkpoint inhibitors.

The results, described by an expert as “very interesting” and a “a bit surprising," focused on the impact of autoimmune antibodies on anti–PD-1 therapy.

A meta-analysis looked at whether or not the sex of a patient had any association with the efficacy of immunotherapy in advanced cancers.

Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018.

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

The recommendations on Trial Reporting in Immuno-Oncology aim to enchance understanding of efficacy and toxicity outcomes in immuno-oncology trials.

The frequency of hepatotoxic immune-related adverse events varied in patients receiving one vs multiple chemotherapy agents.

Dr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.

While previous research has proven the role of MHC-I molecules, a new study in Cell suggests that MHC-II may also serve as a target in immunotherapy.

A study in JAMA Oncology found that a wide range of fatal toxic events can occur with immune checkpoint inhibitors, and the type of event varies by agent.

Taking corticosteroids at the time of treatment initiation with PD-L1 inhibitors may lead to inferior outcomes in patients with non–small-cell lung cancer.

Recent studies on CAR T-cell immunotherapy, and the recent approval of a new agent, add to evidence supporting the efficacy of these therapies.